,i  #aafth ,,congress  #ast ,session    
,h4 ,r4 #dgaj  ,,in ,,the ,,house ,,of  
,,representatives  ,october #ag1        
#bjai,mr4 ,garamendi 7for himself and   
,mrs4 ,hartzler7 introduced the         
following bill2 which was referred to   
the ,committee on ,armed ,services1 and 
in addition to the ,committees on       
,veterans' ,affairs1 and ,financial     
,services1 for a period to be           
subsequently determined by the ,speaker1
 in each case for consideration of such 
provisions as fall within the           
jurisdiction of the committee concerned 
,a ,,bill  ,to direct the ,secretary of 
,defense to include in each national    
defense strategy steps to strengthen the
 ,united ,states industrial base and to 
assure an uninterrupted supply of       
medicines1 and for other purposes4  #a4 
,short title ,this ,act may be cited as 
the ,pharmaceutical ,independence       
,long-,term ,readiness ,reform ,act4    
#b4 ,united ,states medicine supply     
chain  7a7 ,national defense strategy   

,the ,secretary of ,defense shall       
include1 in each national defense       
strategy under section #aac7;g7 of title
 #aj1 ,united ,states ,code1 steps to be
 taken to assure the provision of       
medicines to enable combat readiness and
 force health protection4  7b7 ,report  
to ,congress ,not later than one year   
after the date of the enactment of this 
,act1 the ,secretary of ,defense1 in    
consultation with the heads of other    
appropriate ,federal departments and    
agencies1 shall submit to ,congress a   
report on vulnerabilities to the ,united
 ,states medicine supply chain4 ,such   
report shall include--  7#a7 an         
identification of any finished drugs and
 their essential components including   
raw materials1 chemical components and  
active ingredients necessary for the    
manufacture of medicines whose supply is
 at risk of disruption during a time of 
war or national emergency2  7#b7 an     
identification of shortages of finished 
drugs essential for combat readiness and

 force protection2  7#c7 an             
identification of the defense and       
geopolitical contingencies that are     
sufficiently likely to arise that may   
disrupt1 strain1 compromise1 or         
eliminate supply chains of medicines and
 their essential components and         
recommendations for reasonable          
preparation for the occurrence of such  
contingencies2  7#d7 an assessment of   
the resilience and capacity of the      
current supply chain and industrial base
 to support national defense upon the   
occurrence of the contingencies         
identified in paragraph 7#c71 including 
with respect to--  7,a7 the             
manufacturing capacity of the ,united   
,states2  7,b7 gaps in domestic         
manufacturing capabilities including    
non-existent1 extinct1 threatened1 and  
single-point-of-failure capabilities2   
and  7,c7 supply chains with single     
points of failure and limited           
resiliency2  7#e7 legislative1          
regulatory1 and policy changes necessary

 to avoid1 or prepare for1 contingencies
 identified in the report2 and  7#f7    
recommendations to diversify supply away
 from complete dependency on sources of 
supply in competitor countries and      
politically unstable countries that may 
cut off ,united ,states supply1 and     
address critical bottlenecks and        
mitigate single points of failure and   
limited resilience4  7c7 ,preference for
 medicines  7#a7 ,in general ,except as 
provided in paragraph 7#b7 and under    
section #aajg;a7d7 of title #aj1 ,united
 ,states ,code1 the ,secretary of       
,defense and the ,secretary of ,veterans
 ,affairs--  7,a7 may only acquire and  
purchase ,american-made and ,federal    
,drug ,administration approved raw      
materials1 medicines1 and vaccines for  
the ,department of ,defense2 and  7,b7  
shall use the authorities under the     
,defense ,production ,act to acquire and
 purchase such raw materials1 medicines1
 and vaccines1 recognizing the national 
security vulnerabilities of a dependency

 on a foreign medical supply chain4     
7#b7 ,exception ,paragraph 7#a7 does not
 apply in any case where the ,secretary 
of ,defense determines that a shortage  
of any raw material1 medicine1 or       
vaccine is such that it becomes         
unavoidable to acquire such raw         
material1 medicine1 or vaccine from a   
trusted foreign supplier4  7#c7         
,american-made ,for purposes of this    
subsection1 the term ,american-made     
supplied from1 created1 or supplied by  
the ,united ,states1 including any      
territory or possession of the ,united  
,states4